Why the study?
Do beta-adrenergic blockers improve outcomes in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy?
Do beta-adrenergic blockers improve outcomes in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy?
This review discusses the rationale and clinical evidence for the use of beta-blockers in treating congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports beta-blocker evaluation in idiopathic dilated cardiomyopathy HF; leaves open confirmation by contemporary randomized trials.
Until recently, beta-adrenergic blockers were considered contraindicated for use in patients with heart failure, even though they had been initially given to patients with dilated cardiomyopathy almost 20 years ago. This review discusses the renewed interest in using beta-adrenergic blockers in the treatment of congestive heart failure secondary to idiopathic dilated cardiomyopathy. Rationale for the use of these agents, as well as recent clinical reports on heart function, morbidity (both short- and long-term effects), and mortality are discussed. The possible mechanisms by which beta-blockers improve the status of patients with dilated cardiomyopathy are also reviewed.
No takes yet. Share an insight, caveat, or question.
Finn Waagstein (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: